Tag: Ischemia

While atropine is a standard treatment for certain types of symptomatic bradycardia, its use in a patient experiencing a myocardial infarction (MI) is approached with extreme caution, largely because of its potential to worsen myocardial ischemia. A significant percentage of MI patients experience bradycardia, but the underlying cause dictates the appropriate, and often atropine-free, treatment.

As an anti-ischemic metabolic agent, trimetazidine is widely used in many countries for the treatment of coronary artery disease. It is primarily prescribed for stable angina pectoris when first-line therapies fail to provide sufficient control or are not tolerated. Its unique mechanism of action focuses on optimizing the heart's energy production rather than altering hemodynamics.

Developed in France in the 1970s, trimetazidine is a metabolic agent used primarily as an add-on treatment for angina pectoris, a condition caused by reduced blood flow to the heart. So, what does trimetazidine do to your body? It works by directly altering cellular energy metabolism, protecting heart tissue from the damaging effects of oxygen deprivation.

Originally marketed in France, trimetazidine is a metabolic agent that shifts cardiac energy metabolism to improve efficiency during reduced blood flow. So, **what is trimetazidine used for**? It is primarily indicated as an add-on therapy for patients with stable angina pectoris whose symptoms are not adequately controlled by or who are intolerant to other medications.